Erimos is a growing biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics to treat cancer. Our targeted technology is aimed at eradicating tumors by preventing tumor cell replication and promoting selective tumor cell death (apoptosis).
Erimos has exclusive license for nordihydroguaiaretic acid (NDGA) derivatives from The Johns Hopkins University. We have developed a novel process to extract the NDGA from the resin of the leaves of Larrea tridentate, a desert plant indigenous to the southwestern US and Mexico. Terameprocol (EM-1421), our lead candidate, is a semi-synthetic derivative of NDGA and is designed to target specific differences between normal human cells and those cells that are abnormally aggressively dividing. Our goal is to develop effective medicines with a low toxicity profile for serious diseases with high unmet medical need.
Erimos has several clinical studies ongoing: a Phase I/II study to determine the maximum tolerated dose of terameprocol in adults with recurrent high grade glioma; a Phase I study of intravenous terameprocol in adults with hematological malignancies and a Phase I 24 hour infusion study of terameprocol for refractory and metastatic solid tumors.
Erimos is actively growing and pursuing a near-term business strategy which includes collaborations with interested parties in drug discovery, development and commercialization. Our ongoing research supports a broad-spectrum market opportunity backed by patented global intellectual property.
Erimos has corporate offices, research and development, and laboratory facilities in Raleigh, NC. Additional corporate offices are located in Houston, TX. Erimos also has a processing plant in Juarez, Mexico.
Last Updated: 02-20-2008